Details for Patent: 9,314,475

Which drugs does patent 9,314,475 protect, and when does it expire?

Patent 9,314,475 protects NUZYRA and is included in one NDA.

This patent has fifty-nine patent family members in thirty-one countries.

Summary for Patent: 9,314,475

Title:	Oral and injectable formulations of tetracycline compounds
Abstract:	Injectable and oral formulations of a tetracycline compound are described. In one embodiment, the invention pertains to an oral formulation of a 9-aminomethyl tetracycline compound, or a salt thereof, in tablet form or capsule. The formulations may be used, for example, to treat infections.
Inventor(s):	Johnston; Sean (Doylestown, PA)
Assignee:	Paratek Pharmaceuticals, Inc. (Boston, MA)
Application Number:	12/414,615
Patent Claim Types: see list of patent claims	Composition; Formulation; Compound; Dosage form;

Drugs Protected by US Patent 9,314,475

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Paratek Pharms Inc	NUZYRA	omadacycline tosylate	TABLET;ORAL	209816-001	Oct 2, 2018		RX	Yes	Yes			Y

International Family Members for US Patent 9,314,475

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	076001
Australia	2009229174
Brazil	122020011180
Brazil	PI0909211
Canada	2719751